Technology Listings


56 Results Sort By:
Plant-Based Small Molecules for Treatment of MRSA Infections
Application Small molecule inhibitor of the accessory gene regulator (agr) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Key Benefits Targeted system is non-essential for S. aureus growth, creating less selective pressure for resistance. Does not harm beneficial host bacteria. May potentially be used concomitantly...
Published: 4/23/2020       Inventor(s): Cassandra Quave, Akram Salam, Gina Porras Brenes, James Lyles
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer. Key Benefits Novel molecule. Novel target presents new path to lung cancer treatment. Potentially extend survival rate of lung cancer patients. Market Summary Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020       Inventor(s): Xingming Deng
Reprogramming Human Urine Stem Cells into Vascular Tissue
Application System to generate vascular progenitor cells within naturally constructed (or formed) biomatrices from urine cells. Key Benefits Nearly limitless supply of source cells. Non-invasive method for harvesting source cells. Efficient endothelial cell generation with fewer steps and faster generation time than current standard for differentiating...
Published: 1/23/2020       Inventor(s): Young-Sup Yoon, Young-Doug Sohn, Sang-Ho Lee
Small Molecule for Treatment-Resistant Lung Cancer
Application Small molecule agonist for treating cancers involving KRAS mutations. Key Benefits Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC). Selective for mutant KRAS lung cancer cells over normal cells. Non-toxic to normal cells. Market Summary Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020       Inventor(s): Xingming Deng
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders. Key Benefits Specifically targets NMDARs that contain the GluN2C/2D subunit. Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators. Market...
Published: 1/10/2020       Inventor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
Antibacterial Treatment for Gum Disease
Application Small molecules that inhibit oral bacteria growth to treat gum disease and prevent tooth decay. Key Benefits Inhibits S. mutans biofilm formation. Reduces the number of bacteria by working in a bactericidal, as opposed to bacteriostatic, manner. Market Summary Periodontitis is a gum infection in which gums become inflamed due to...
Published: 12/2/2019       Inventor(s): William (Bill) Wuest, Amy Solinski, Marisa Kozlowski, Young Eun Lee, Thomas Paniak, Cristian Ochoa
TGFβR3-based Biomaterial to Treat Bone Damage
Application PEG-MAL (Poly(ethylene glycol) methyl ether maleimide) polymer gel composition containing soluble TGFβ3R or embedded with modified TGFβ3R over-expressing cells for bone growth and repair therapy. Key Benefits Targets a non-BMP2 signaling pathway to improve BMP signaling. •Avoids complications associated with BMP2. Market...
Published: 9/20/2019       Inventor(s): Steven Goudy
Subunit-Selective Modulator for Treatment of Neurological Disorders
Application Subunit-selective GluN2C and GluN2D positive allosteric modulators of N-methyl-D-aspartic acid receptors (NMDAR) for treatment of neurological disorders. Key Benefits Specifically targets GluN2C/D subunits for positive modulation of NMDAR activity. Higher potency compared to non-selective modulators. Improved drug-like properties...
Published: 8/26/2019       Inventor(s): Matthew Epplin, David Menaldino, Stephen Traynelis, Dennis Liotta
Small Molecule Inhibitors of Mcl-1 as Anti-Cancer Agent
Application Myeloid cell leukemia 1 (Mcl-1) inhibitor to enhance DNA replication stress sensitivity for cancer therapy. Key Benefits Inhibits DNA repair in cancer cells. Used in combination with existing cancer therapy. Market Summary Chemoresistance occurs when cancer cells develop resistance to chemotherapy drugs, and appearance of chemoresistance...
Published: 6/24/2019       Inventor(s): Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 6/18/2019       Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
1 2 3 4 5 6